Associated equity: Newron Pharmaceuticals
Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting schizophrenia.
Newron Pharmaceuticals — 4 videos in collection
Newron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders. The company is progressing its lead asset, evenamide, through late-stage development for treatment-resistant schizophrenia (TRS), a disease area that has seen limited innovation in recent years and therefore presents a potentially sizeable commercial opportunity.
We highlight five key reasons why Newron may be considered a compelling investment opportunity:
To learn more about Newron Pharmaceuticals, see our latest research.